Alpha Emitter Radium-223 and Survival in Metastatic Prostate CancerChris Parker, Oliver Sartor, Isabel Syndikus et al.|New England Journal of Medicine|2013Cited by 3.3k
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trialNicholas D. James, Mahesh Parmar|The Lancet|2015Cited by 2k
Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trialOliver Sartor, Christopher Parker, Robert L. Coleman et al.|The Lancet Oncology|2014Cited by 491
Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trialKarim Fizazi, Mika Mustonen, Christophe Massard et al.|The Lancet Oncology|2014Cited by 194
EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort†J. Alfred Witjes, Donna E. Hansel, Marek Babjuk et al.|European Urology|2019Cited by 191